Search

Radio broadcaster, Peter White, and ophthalmologist professor Ian Pearce join this webinar to bid farewell to Cathy Yelf, the Macular Society's chief executive, who is retiring after nearly a decade of dedicated service. They discuss the progress in macular research over the years, share insights on current developments, and explore their hopes for the future. Watch the video below. 

Professor Jacqueline van der Spuy from the UCL Institute of Ophthalmology joins us to discuss the development of treatments for Doyne honeycomb retinal dystrophy, an inherited juvenile macular dystrophy affecting sight from early adulthood.

Join us as we explore the latest developments from OKKO Health, which is developing a home-monitoring app to allow people with macular disease to better monitor their vision from home. OKKO Health has developed an app to help people to monitor their sight between clinic visits, through simple puzzle games. The smartphone app, which is still in development, uses software similar to that of a video game to assess visual health.

Professor Linda Troeberg from the University of East Anglia joins us to discuss research updates her Macular Society research project looking into the development of treatments for Sorsby's fundus dystrophy, an inherited juvenile macular dystrophy.

Dr Ashley Wood and Vera Silva from Cardiff University join our My Macular and Me webinar to discuss new research into early age-related macular degeneration (AMD). Dr Wood’s team is developing technology to detect early changes in vision, especially difficulties adjusting to low light, which could help diagnose AMD sooner.

New research has found that taking a daily vitamin and mineral supplement can slow the progression of late-stage dry age-related macular degeneration (AMD), otherwise known as geographic atrophy (GA).

Professor Richard Gale covers all the exciting developments for wet and dry AMD, as well as diabetic macular oedema. From recently approved treatments in the UK to the growing role of biosimilars, you can find out about the progress being made. Professor Gale will also reveal what’s in the pipeline, and why there’s reason to feel hopeful for the future as we move into 2025 and beyond.

Lytenava (bevacizumab gamma), is the first licensed version of Avastin for wet age-related macular degeneration. The treatment was approved by the National Institute for Health and Care Excellence (NICE) for use in the NHS last year.

There are so many low vision aids (LVAs) on the market, making it difficult to know which one is right for you. But what really works? And which devices offer the best improvements to quality of life for those living with macular disease? 

Current treatments for wet age-related macular degeneration (AMD) have been life changing for many, helping to maintain vision. However, not all patients respond well to anti-VEGF injections, highlighting the need for alternative treatments. Professor Dulcie Mulholland and PhD student Elisha Griffin have been exploring whether 'homoisoflavonoids', found in rare hyacinth plants, could help prevent abnormal blood vessel growth in the macula.